135P First-in-human phase I trial of SRF617, a potent inhibitor of CD39 activity, as monotherapy or in combination, in patients (pts) with advanced solid tumors
Title:
135P First-in-human phase I trial of SRF617, a potent inhibitor of CD39 activity, as monotherapy or in combination, in patients (pts) with advanced solid tumors
Author:
Patnaik, A. Mehmi, I. Strauss, J. Xing, Y. Jamal, R. O'Neill, A. Lake, A.C. Koseoglu, S. Warren, M.C. Chung, J-K. Alika, A. Lis, R. Rasco, D. Salawu, A.T. Chow, W. Spreafico, A.